The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants
NCT ID: NCT02962583
Last Updated: 2020-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
152 participants
INTERVENTIONAL
2017-01-31
2019-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals
NCT02893943
Effects of a Probiotic on Body Weight
NCT01106924
The Influence of Probiotics on Body Weight and Composition
NCT02465294
Efficacy of a Probiotic Formulation on Energy Balance in Overweight Subjects
NCT01066260
A Study to Evaluate the Effect of SlimBiotics Probiotic Formula on Weight Management and Metabolic Health Outcomes
NCT05917314
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Daily probiotic consumption
Weight loss
Probiotic Formula
Placebo
Daily placebo consumption
Weight loss
Placebos
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Weight loss
Probiotic Formula
Placebos
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI between 27.0 and 39.9 kg/m2
* Sedentary to moderate active (less than 30 minutes of physical activity, 3 times per week)
* Willingness to complete questionnaires, records, and diaries associated with the study and to complete all study visits
* Willingness to discontinue consumption of fermented foods or probiotics (e.g. yoghourts, with live, active cultures or supplements), laxatives, prebiotics and any substance for body weight control
* Willingness and ability to provide informed consent in French
* Willingness to receive random assignment to probiotic or placebo supplementation
* Committed to losing weight over the 12-week study period
Exclusion Criteria
* Use of another investigational product within three months of the pre-baseline period.
* Known to be pregnant or breast-feeding or planning on becoming pregnant in the next 18 months.
* Women of child-bearing potential not using effective contraception which include:
* Hormonal contraceptives including combined oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormonal implants
* Intrauterine devices (IUD) or Intrauterine system (IUS)
* Tubal ligation
* Vasectomy of partner
* Double barrier method (use of physical barrier by both partners, e.g. male condom and diaphragm, male condom and cervical cap)
* Positive pregnancy test in women of child-bearing potential
* Menopausal women
* Allergic to milk, soy, or yeast
* Weight gain or loss of at least 10 lbs in previous three months
* Inflammatory bowel syndrome, celiac disease, short bowel syndrome, or any other malabsorptive syndrome
* Uncontrolled angina within the past six months
* Insulin-dependent diabetes (oral medications are not exclusionary)
* Serious and/or unstable medical conditions (e.g. cardiovascular, renal, lung, psychiatric illness, bleeding disorders, etc.)
* Cancer treatment (radiation, chemotherapy, surgery) within past six months or any other treatment or condition known to weaken the immune system (such as systemic corticosteroids or HIVIAIDS).
* Any physical condition deemed likely to significantly interfere with individuals' ability to participate in a nutritional intervention.
* Currently or at any point during the study participating in Weight Watcher's or another weight loss program or taking a medication for weight loss.
* Under antibiotics or treatments (medication or nutritional program) affecting body weight Intake and/or energy expenditure
* History of drug or alcohol (\> 9 drinks weekly) abuse
* Abnormal thyroid hormone levels
* Immune-compromised conditions
* Participant experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lallemand Health Solutions
INDUSTRY
Laval University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angelo Tremblay
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angelo Tremblay, Ph.D
Role: STUDY_DIRECTOR
Laval University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PEPS - Université Laval
Québec, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Choi BS, Brunelle L, Pilon G, Cautela BG, Tompkins TA, Drapeau V, Marette A, Tremblay A. Lacticaseibacillus rhamnosus HA-114 improves eating behaviors and mood-related factors in adults with overweight during weight loss: a randomized controlled trial. Nutr Neurosci. 2023 Jul;26(7):667-679. doi: 10.1080/1028415X.2022.2081288. Epub 2022 Jun 17.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLIN-21-012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.